PTGX
Protagonist Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -15.4% ·
share flow -5.2% ·
net new positions -18.2%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 4.85K | $678,004 | n/a | −1 |
| Q2 2026 | 104 | +1 | 45.40M | $5.56B | +7 | −8 |
| Q1 2026 | 108 | -1 | 49.99M | $5.27B | +9 | −10 |
| Q4 2025 | 107 | +4 | 45.87M | $4.01B | +4 | n/a |
| Q3 2025 | 17 | 0 | 26.31M | $1.75B | +2 | −2 |
| Q2 2025 | 14 | -1 | 22.53M | $1.25B | +1 | −2 |
| Q1 2025 | 12 | +1 | 7.51M | $363.26M | +3 | −2 |
| Q4 2024 | 11 | -2 | 7.82M | $302.00M | n/a | −2 |
| Q3 2024 | 12 | +2 | 4.92M | $221.52M | +3 | −1 |
| Q2 2024 | 10 | n/a | 7.44M | $257.83M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 3.33M | n/a | $128.58M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 1.39M | +6.3% | $53.76M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 1.38M | +0.2% | $53.17M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 4 | Wellington Management ✦ | 940.08K | +3025.4% | $36.29M | 0.0% | ▲ Add | 2 | SEC ↗ ×6 |
| 5 | Renaissance Technologies ✦ | 221.17K | +53.4% | $8.54M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Arrowstreet Capital ✦ | 216.07K | +36.7% | $8.34M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 164.15K | +3163.3% | $6.34M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 8 | AQR Capital Management ✦ | 150.10K | +9.4% | $5.79M | 0.0% | ▲ Add | 3 | SEC ↗ ×4 |
| 9 | Marshall Wace ✦ | 19.72K | -93.8% | $761,038 | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 10 | D. E. Shaw & Co. ✦ | 5.70K | -78.7% | $220,174 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 5.66K | -0.9% | $218,399 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Adage Capital Partners | $54.04M | was 0.1% |
| Point72 Asset Management | $9.67M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 310 holders, 71.79M shares, $7.31B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 46.03K sh · $6.53M
Officer · 12.60K sh · $1.79M
Officer, Director · 7.28K sh · $1.05M
Officer, Director · 63.55K sh · $9.29M
Officer, Director · 54.17K sh · $7.90M
Officer, Director · 34.24K sh · $5.09M
Officer, Director · 65.76K sh · $9.81M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology